跳至主要内容
临床试验/NCT00581620
NCT00581620已完成4 期

To Evaluate the Humoral Immune Response to a Conjugated Pneumococcus Vaccine 7-Valent (Prevenar®) in Children From High Risk Groups.

Wyeth is now a wholly owned subsidiary of Pfizer0 个研究点目标入组 160 人开始时间: 2002年11月1日最近更新:
适应症

试验速览

阶段
4 期
状态
已完成
发起方
入组人数
160
主要终点
To determine immunogenicity of the heptavalent CRM197 pneumococcal conjugate in children with immunodeficiency condition

研究概览

简要总结

To determine immunogenicity of the heptavalent CRM197 pneumococcal conjugate in children with immunodeficiency condition. To evaluate tolerability of Prevenar® in that population.

详细描述

This study will require 24 months to be completed. Each child will participate for a period of time according to age of the 1st dose of vaccination: infants up to 6 months of age will be evaluated for 5 months; infants between 7 to 11 months will be evaluated for 3 months; children between 12 months up to 9 years of age will be evaluate for 2 months

研究设计

研究类型
Interventional
分配方式
Randomized
干预模型
Parallel
主要目的
Prevention
盲法
None

入排标准

年龄范围
2 Months 至 9 Years(Child)
性别
All
接受健康志愿者

入选标准

  • Children between 2 months to 9 years old.
  • Children with HIV+; Sickle Cell disease; Neprotic symdrome; Chronic pulmonary disease
  • No history of seizures

排除标准

  • 未提供

结局指标

主要结局

To determine immunogenicity of the heptavalent CRM197 pneumococcal conjugate in children with immunodeficiency condition

时间窗: 4 months

次要结局

  • To evaluate tolerability of Prevenar* in that population.(4 months)

研究者

发起方
Wyeth is now a wholly owned subsidiary of Pfizer
申办方类型
Industry

相似试验